Skip to main content

Table 2 Time-dependent characteristics in patients with and without VDRA therapy

From: Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study

Characteristic Follow-up time (months) Total VDRA No VDRA p-value
Serum calcium (mg/dl) 6 8.8 8.8 8.8 0.34
12 8.9 8.9 8.8 0.02
18 8.9 8.9 8.8 0.26
24 9.0 9.0 9.0 0.2
30 9.0 8.9 8.9 0.85
36 8.9 8.9 9.0 0.11
Serum phosphorus (mg/dl) 6 5.1 5.0 5.2 0.17
12 5.2 5.2 5.3 0.29
18 5.0 5.0 5.1 0.44
24 4.9 4.9 4.9 0.93
30 4.9 4.9 4.9 0.56
36 4.8 4.8 4.8 0.49
PTH (pg/ml) 6 225 313 157 <0.01
12 197 245 141.3 <0.01
18 201 227 155 <0.01
24 212 240.3 155 <0.01
30 247 268.3 148.5 <0.01
36 254 260 197.5 0.15
Serum albumin (g/dl) 6 3.60 3.55 3.55 0.09
12 3.70 3.70 3.60 0.03
18 3.75 3.78 3.70 0.19
24 3.76 3.80 3.69 0.06
30 3.74 3.76 3.73 0.51
36 3.80 3.72 3.81 0.42
Hemoglobin (g/dl) 6 10.9 11.0 10.9 0.08
12 11.4 11.4 11.5 0.79
18 11.5 11.4 11.5 0.86
24 11.3 11.2 11.5 0.05
30 11.2 11.2 11.3 0.23
36 11.7 11.4 11.9 0.07
  1. PTH = parathyroid hormone. P-values denote comparisons between VDRA and no VDRA groups. Statistically significant p-values are highlighted in bold.